BiotechTube
Finch Therapeutics

Finch Therapeutics

Somerville, United States· Est.
finchtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $153M

Overview

Finch Therapeutics, founded in 2014, was a clinical-stage microbiome company that developed oral microbiome drugs. Its lead candidate, CP101, showed positive Phase 2 results for preventing recurrent C. difficile infection but its Phase 3 trial was discontinued in January 2023. The company has since shifted its strategy away from clinical development, undergoing delisting from Nasdaq and deregistration with the SEC in 2024, and is now focused on monetizing its IP portfolio and assets through partnerships.

Infectious Disease

Technology Platform

Platform for developing defined, orally administered microbial consortia based on insights from human microbiota transplantation (HMT/FMT).

Funding History

3
Total raised:$153M
Series C$90M
Series B$53M
Series A$10M

Opportunities

The primary opportunity is to monetize a robust IP estate built during the company's pioneering phase in microbiome therapeutics.
This portfolio could be valuable to larger pharma or biotech companies seeking to enter or expand in the microbiome space without early-stage R&D.
The underlying modality still holds significant long-term promise across many disease areas.

Risk Factors

The company faces existential risk if it cannot sell or license its IP assets.
The value of the IP is uncertain and may be time-sensitive as science advances.
Operating as a non-revenue-generating shell company incurs administrative costs with no guaranteed payoff.

Competitive Landscape

The competitive landscape for microbiome therapeutics includes companies like Seres Therapeutics (which has an approved product for rCDI), Vedanta Biosciences, and others. Finch's shift to an IP-focused model places it in competition with other asset sellers rather than as a direct clinical competitor. Its success depends on the uniqueness and breadth of its patent claims relative to others in the field.

More companies in United States →